In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Check-Cap (CHEK), with a price target of $4.00. The company’s shares closed last Monday at $3.07.
According to TipRanks.com, Chen is a top 25 analyst with an average return of 76.9% and a 63.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.
Currently, the analyst consensus on Check-Cap is a Moderate Buy with an average price target of $4.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.49 and a one-year low of $0.24. Currently, Check-Cap has an average volume of 26.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in developing gastrointestinal imaging devices. It develops capsule-based system that utilizes low-dose X-rays to detect polyps, masses and colorectal cancer screening. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
